ClinicalTrials.gg
RecruitingNCT07223255MedDietCFUpdated Jul 2, 2026

Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet

An interventional study of Mediterranean diet in Cystic Fibrosis (CF) and Cystic Fibrosis Gastrointestinal Disease, sponsored by Dartmouth-Hitchcock Medical Center. Recruiting at 2 sites in United States. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Dartmouth-Hitchcock Medical Center · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Planned enrollment
353rd of 517
20 · median 36
Started
2026
with 15 others
No phase
155 of 717
17 open now
Primary completion
2027-06
later than 47 of 108 live
Registered
701st of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 353rd largest by planned enrollment of the 517 interventional ones that give a count, is one of 16 that started in 2026, is one of 155 with no phase, reaches primary completion later than 47 of the 108 other live ones, and was the 701st registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

There is no study to date that has evaluated the impact or effect of a Mediterranean diet in children with CF. The goal of this study would be to help provide better guidance around questions the investigators, as CF care providers continue to receive from patients and families about how to best promote overall health in pediatric cystic fibrosis from a dietary perspective. Currently, the updated nutritional recommendations are variable and broad. Parents continue to search for more concrete guidance about how best to promote long-term health given the ever-increasing life expectancy of cystic fibrosis patients in this new area of advanced therapeutics. Given the changing landscape of the CF care in general, children are less likely to struggle with early life malnutrition, and it is becoming increasingly clear that high fat, high calorie diets are not beneficial nor are necessary for all children with CF.

Read the detailed description

The dietary needs of children with Cystic Fibrosis continue to change. With the advent of highly effective modulator therapy, these needs are profoundly shifting away from the standard advice of high calorie, high fat to varied, regular and moderated calorie. Obesity is a problem the investigators now confront with regularity and has prompted the need for more specific, dietary advice to parents who are eager to find sustainable meal plans that promote health overall.

There is significant data to suggest that the Mediterranean Diet is the pinnacle of dietary health in everything from metabolic syndrome to ADHD in children. As the investigators look to shift away from the standard approach, the investigators are left to consider how specific dietary intervention may be able to support children with cystic fibrosis. Recent studies suggest Mediterranean diet and those similar were associated with increased abundance of fiber degrading bacteria like Ruminococcus as well as subclinical decreases in fecal calprotectin, a marker of gastrointestinal inflammation. In other inflammatory disease, the Mediterranean diet has also been considered as an adjunctive therapy in mild Crohn's and well as ulcerative colitis disease given its anti-inflammatory properties. Specifically in UC, notable microbiome shifts toward increased production of short chain fatty acids which can have a protective, immunomodulatory role in the gut. Data has shown that the CF gut microbiome is different than it's healthy counterparts and often described as a mix of dysbiosis and low grade chronic inflammation. If the investigators could address the underlying inflammation and dysbiosis in a substantial way with an anti-inflammatory dietary intervention, there is potential to decrease the burden of GI disease and symptomatology that persists despite the widespread use of highly effective modulator therapy.

AIM 1: To test the hypothesis that adherence to a Mediterranean Diet will result in alterations to the gastrointestinal microbiome. The investigators would plan to collect fecal samples for microbiota sequencing before starting a strict Mediterranean diet and then again after completion to assess for specific alterations or signatures in microbial diversity as well as other cytokine or metabolomic alterations. Our translational research core already has infrastructure set up for this process through the Dartmouth Infant and Child CF Cohort Study and many of our families are already familiar with this process.

AIM 2: To test the hypothesis that adherence to a Mediterranean Diet will result in reduction in subclinical markers of gastrointestinal inflammation. Stool calprotectin measurements from samples before and after the study period will allow us to assess for alterations.

AIM 3: To test the hypothesis that adherence to a Mediterranean Diet will result in improvement in gastrointestinal symptoms, the investigators would also employ the PAGY-SYM, which is a widely used gastrointestinal symptom tracker to identify any significant changes in GI symptomatology before and after the anticipated diet window.

AIM 4: To test the hypothesis that adherence to a Mediterranean Diet will result in normalization of anthropometric data the investigators will collect clinical information on subject weight, height, BMI Z score as well as mid upper arm circumference as a way to measure relative nutritional status and fat storage.

Study Endpoints:

Primary: Subjects will adhere to 6 months of exclusive Mediterranean Diet and have post diet intervention analysis of 16s and metagenomic sequencing, cytokine and metabolomic analysis for microbiome assessment.

Secondary: Fecal calprotectin as a marker of intestinal inflammation. Patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) for symptom reporting.

03

Conditions studied

  • Cystic Fibrosis (CF)
  • Cystic Fibrosis Gastrointestinal Disease

Browse trials for

Keywords

  • cfmed
  • meddiet
  • meddiet cf
  • mediterannean diet
  • cystic fibrosis
  • CF with Mediterranean diet
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female pediatric patient with cystic fibrosis age 3 and older
  • Nutritional status defined as a Z-score of at least -1 or above
  • Confirm diagnosis of CF defined by 2 CF causing mutations on genetic testing or sweat chloride greater than 60 mEq/L
  • Children with pancreatic insufficient CF and on PERT
  • Children with pancreatic sufficient CF not on PERT
  • Child must be on a full, solids based diet
  • Family willing to child adhere to an exclusive Mediterranean style diet for a period of 6 months
  • Child must be able to follow-up at regular CF clinic visits and attend any additional study visits if necessary

Exclusion criteria

Exclusion Criteria:

  • Children with malnutrition
  • Children who require nutritional supplementation via any type of feeding tube
  • Children with poorly controlled CF lung disease
  • Children with advanced CF liver disease
  • Children with a comorbid gastrointestinal disease such as celiac disease, Crohn's disease or other malabsorptive process to be reviewed by PI
  • Children with significant food allergies or other gastrointestinal allergy
  • Family is unwilling to adhere to prescribed dietary intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    med diet

    Mediterranean diet

    Other: Mediterranean diet

Interventions

  • OtherMediterranean diet

    Patients enrolled in this study will follow a Mediterranean diet for a 6 month period.

06

What researchers measure

Primary outcomes

  1. Metagenomic sequencing

    Subjects will adhere to 6 months of exclusive Mediterranean Diet and have post diet intervention analysis of 16s and metagenomic sequencing, cytokine and metabolomic analysis for microbiome assessment.

    Time frame: 6 months

Secondary outcomes

  1. Fecal calprotectin

    Fecal calprotectin as a marker of intestinal inflammation. Patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) for symptom reporting.

    Time frame: 6 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2027, 9 months later.

Of 214 non-industry interventional studies with no phase under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 9 months is below that.

Counting every sponsor, half of 229 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 31, 2025
StartEst.
Sep 1, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223255
Responsible party
Julie.L.Sanville (Assistant Professor of Pediatrics, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Oct 31, 2025
Start date
Sep 1, 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Julie L Sanville, MD
Contact
Julie.L.Sanville@hitchcock.org
603-653-9666
Sarah P Winslow, RN
Contact
Sarah.P.Winslow@hitchcock.org
603-629-1849

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion